The US Food and Drug Administration (FDA) has approved a new once-daily single inhaler triple therapy for treatment of certain adults with chronic obstructive pulmonary disease (COPD).  Trelegy Ellipta (furoate, umeclidinium, vilanterol) is indicated for patients on a fixed-dose combination...

Around 49 million American adults were still using tobacco products in 2015, according to new data published by the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration’s (FDA) Center for Tobacco Products.  The Morbidity and Mortality Weekly Report...

The US Food and Drug Administration (FDA) has approved Sunovion’s Lonhala Magnair (glycopyrrolate), making it the first nebulized long-acting muscarinic antagonist (LAMA) treatment in the United States for patients with chronic obstructive pulmonary disease (COPD). It is expected to appear in...

GlaxoSmithKline’s once-daily triple therapy, the Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol), is superior to dual combination therapies in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbations, new research...

Americans suffering from severe emphysema now have a new treatment option available following the decision by the US Food and Drug Administration (FDA) to approve the Zephyr Endobronchial Valve, or Zephyr Valve. The device, marketed by Pulmonx Inc, is placed into diseased areas of the lungs by a...

The US Food and Drug Administration (FDA) has released the first of two new pieces of draft guidance that may eventually enable e-cigarette manufacturers to apply for regulated drug status for their products.  FDA Commissioner Scott Gottlieb, MD, said there is “no greater impact we can...